Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
Thyroid : Official Journal of the American Thyroid Association|September 23, 2022
Case Report of <i>CCDC149-ALK</i> Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid CarcinomaHannah Lee, Vimal Krishnan, Lori J Wirth, et al.
Investigational New Drugs|February 18, 2011
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxelMichael Millward, Paul Mainwaring, Alain Mita, et al.
Oral Oncology|September 24, 2017
Predictors of survival in head and neck mucosal melanomaMatthew Q Schmidt, John David, Emi J Yoshida, et al.
Investigational New Drugs|February 15, 2017
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumorsMonica Mita, Siqing Fu, Sarina Anne Piha-Paul, et al.
Molecular Cancer Therapeutics|December 29, 2011
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumorsRazelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2008
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignanciesMonica Mita, Alain Mita, John Sarantopoulos, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumorsJohn Nemunaitis, Alain Mita, Joe Stephenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumorsQuincy Chu, Alain Mita, Bahram Forouzesh, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEmma Guttman-Yassky, Alain Mita, Maja De Jonge, et al.
Pageof 6